The role of thromboxane A2 in complement activation-related pseudoallergy

Tamás Gyula Fülöp; Josbert M. Metselaar; Gert Storm; János Szebeni

doi:10.1515/ejnm-2016-0039

The role of thromboxane A₂ in complement activation-related pseudoallergy

Tamás Gyula Fülöp^*
, Josbert M. Metselaar
, Gert Storm
, János Szebeni

^*Corresponding author for this work

Biomaterials Science and Technology

Research output: Contribution to journal › Review article › Academic › peer-review

2 Citations (Scopus)

Abstract

Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A₂ (TXA₂). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

Original language	English
Pages (from-to)	59-67
Number of pages	9
Journal	European journal of nanomedicine
Volume	9
Issue number	2
DOIs	https://doi.org/10.1515/ejnm-2016-0039
Publication status	Published - 1 Apr 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

adverse drug reactions
allergy
anaphylatoxins
anaphylaxis
animal models
hemodynamic changes
hypersensitivity reactions
immune toxicity
pseudoallergy
NLA

Access to Document

10.1515/ejnm-2016-0039

Cite this

@article{6e490d0c7ba0486891ae145eaab2d328,

title = "The role of thromboxane A2 in complement activation-related pseudoallergy",

abstract = "Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.",

keywords = "adverse drug reactions, allergy, anaphylatoxins, anaphylaxis, animal models, hemodynamic changes, hypersensitivity reactions, immune toxicity, pseudoallergy, NLA",

author = "F{\"u}l{\"o}p, \{Tam{\'a}s Gyula\} and Metselaar, \{Josbert M.\} and Gert Storm and J{\'a}nos Szebeni",

year = "2017",

month = apr,

day = "1",

doi = "10.1515/ejnm-2016-0039",

language = "English",

volume = "9",

pages = "59--67",

journal = "European journal of nanomedicine",

issn = "1662-5986",

publisher = "De Gruyter Open Ltd.",

number = "2",

}

TY - JOUR

T1 - The role of thromboxane A2 in complement activation-related pseudoallergy

AU - Fülöp, Tamás Gyula

AU - Metselaar, Josbert M.

AU - Storm, Gert

AU - Szebeni, János

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

AB - Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

KW - adverse drug reactions

KW - allergy

KW - anaphylatoxins

KW - anaphylaxis

KW - animal models

KW - hemodynamic changes

KW - hypersensitivity reactions

KW - immune toxicity

KW - pseudoallergy

KW - NLA

UR - https://www.scopus.com/pages/publications/85017326437

U2 - 10.1515/ejnm-2016-0039

DO - 10.1515/ejnm-2016-0039

M3 - Review article

AN - SCOPUS:85017326437

SN - 1662-5986

VL - 9

SP - 59

EP - 67

JO - European journal of nanomedicine

JF - European journal of nanomedicine

IS - 2

ER -